Complement 3 glomerulopathy

MONDO:0018013

A rare primary membranoproliferative glomerulonephritis characterized by complement dysregulation occurring in the fluid phase and in the glomerular microenvironment, which results in prominent complement C3 deposition in kidney biopsy samples.

Also known as: C3 glomerulopathy, C3G, non-Ig-mediated MPGN, non-Ig-mediated membranoproliferative glomerulonephritis, non-immunoglobulin-mediated MPGN, non-immunoglobulin-mediated membranoproliferative glomerulonephritis

42 clinical trials for this condition and its sub-types.

Follow this condition — get notified about new trials

Sub-types

C3 glomerulonephritis (7) Dense deposit disease (5) Complement factor H deficiency (0) Immunodeficiency with factor H anomaly (0)

Broader categories

Disease (618) Inflammatory disease (310) Kidney disorder (202) Urinary system disorder (62) Glomerulonephritis (28) Nephritis (16) Human disease (14) Glomerular disorder (8) Disease by body system or component (0) Disease by developmental or physiological process (0)

Trials to join now! 17 Not yet recruiting 6 Not yet finished but already full! 10 Completed 8 Terminated 1

New drug OMS721 tested for rare kidney conditions

Disease control Terminated

This study tested a drug called OMS721 in 31 people with certain kidney diseases, including IgA nephropathy and lupus nephritis. The main goal was to check if the drug is safe and if it reduces protein in the urine, a sign of kidney damage. The study was stopped early, so results…

Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control

Last updated Jun 27, 2026 12:02 UTC

Complement 3 glomerulopathy

Sub-types

Broader categories

New drug OMS721 tested for rare kidney conditions